Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764439 | 1.00 | NPC1 (0.40) | NPC1PKMRAB9ACA1CA2 | |
| SCHEMBL6760803 | 0.90 | MEN1 (0.41) | TSHRNR1H2NR1H3HPGD | |
| SCHEMBL6760804 | 0.90 | MEN1 (0.41) | TSHRNR1H2NR1H3HPGD | |
| SCHEMBL6757323 | 0.82 | PKM (0.38) | PKMTSHRHPGD | |
| SCHEMBL6757328 | 0.82 | PKM (0.38) | PKMTSHRHPGD | |
| SCHEMBL6759793 | 0.81 | GPR183 (0.45) | NPC1RAB9AMTNR1BGPR183 | |
| SCHEMBL6759789 | 0.81 | GPR183 (0.45) | NPC1RAB9AMTNR1BGPR183 | |
| SCHEMBL6759749 | 0.77 | NPC1 (0.45) | NPC1RAB9AMTNR1BGPR183 | |
| SCHEMBL6757351 | 0.76 | GPR183 (0.42) | NPC1RAB9AMTNR1BGPR183 | |
| SCHEMBL6757349 | 0.76 | GPR183 (0.42) | NPC1RAB9AMTNR1BGPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | NPC1 566/4885PKM 204/4885RAB9A 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.